LifeMD Reports Q3 2026 Revenue Decline Amid Branded Pharmaceutical Implementation Delays
LifeMD (LFMD) reported third-quarter revenue of $44.6 million, a 7% year-over-year decline that missed management guidance. The shortfall was attributed to timing delays in the implementation of branded pharmaceutical fulfillment programs. Despite the revenue miss, the company showed significant progress toward operational breakeven, with Adjusted EBITDA improving by $3.1 million sequentially to negative $0.4 million. The company is pivoting its strategy from aggressive top-line growth to improved unit economics, evidenced by a 34% sequential reduction in marketing expenses and a 40% decrease in customer acquisition costs since June 2026. While the revenue run rate was revised downward to $200 million, LifeMD saw a 58% year-over-year increase in pharmacy shipment volume and a tripling of compounded therapy orders compared to the previous quarter.
Topics: EBITDA GLP-1 medications pharmaceutical fulfillment revenue miss subscriber growth